QST-Pupillometry in Sickle Cell Disease Patients



Status:Active, not recruiting
Conditions:Anemia, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:13 - 30
Updated:4/17/2018
Start Date:August 2013
End Date:December 2018

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Quantitative Sensory Testing and Pupillometry in Sickle Cell Disease Patients.

There has been little progress for effective treatment of pain in sickle cell disease (SCD)
patients. Many organizations have recognized that understanding the causes and reducing the
burden of pain in SCD is critical in order to improve the quality of life in SCD patients. As
patients with SCD face the challenge of living with both acute and chronic pain which is
often improperly treated, our translational and interdisciplinary project aims to identify
objective measures of pain sensitivity and its biochemical and genetic correlates. We
hypothesize that SCD patients will have decreased tolerance to thermal and electrical
stimuli.


Inclusion Criteria:

- SCD with severe phenotype (HbSS, HbSbeta0 thalassemia, HbSOArab)

- Relatives of SCD patients who do not have sickle cell trait or SCD; healthy controls

Exclusion Criteria:

- Completed overt clinical stroke or transient ischemic attack;

- Known severe vasculopathy or Moyamoya disease on brain MRA (Magnetic Resonance
Angiography).

- history of having consumed alcohol within the last 12 hours prior to testing.
We found this trial at
1
site
Childrens National Medical Center
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Principal Investigator: Zena Quezado, MD
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials